不可逆电穿孔消融在肝癌治疗中的全流程管理策略

肝癌电子杂志 ›› 2021, Vol. 8 ›› Issue (2): 57-61.

不可逆电穿孔消融在肝癌治疗中的全流程管理策略

武慧铭¹, 赵建军^2,*

1.哈尔滨医科大学附属第三临床医学院医学影像学系,黑龙江哈尔滨 150081;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京 100012

收稿日期:2020-11-30 发布日期:2021-07-16
通讯作者: *赵建军,E-mail: zjj8424@sina.com
作者简介:武慧铭, 本科在读,哈尔滨医科大学附属第三临床医学院,医学影像学系
基金资助:
中国传染病国家重点项目（2018ZX10723204005003）,中国癌症基金会北京希望马拉松专项资金（LC2020A35 ）; 深圳市“医疗卫生三名工程”项目（SZSM202011010）

The whole process management strategy of irreversible electroporation in the treatment of liver cancer

Wu Huiming¹, Zhao Jianjun^2,*

1. Undergraduate of Medical Imaging, the Third Affiliated Clinical College of Harbin Medical University, Harbin 150081 Heilongjiang, China;
2. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Oncology/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100012, China

Received:2020-11-30 Published:2021-07-16

摘要/Abstract

摘要： 自2015年,不可逆电穿孔消融引进我国并批准应用于临床。至今,我国部分较大规模的中心及其专家已在该技术的应用上积累了丰富的经验,但是作为一项新技术,其在推广及临床应用方面还存在较多盲点和误区。因此,本文主要从不可逆电穿孔消融治疗肝癌的基本原理和优势、术前病例筛选、术中操作要点、术后管理、疗效评估、安全性与并发症和技术劣势与局限性等方面进行阐述和探讨,并对不可逆电穿孔消融的未来做一展望。

关键词: 不可逆电穿孔消融, 肝癌, 全流程管理策略

Abstract: Since 2015, irreversible electroporation has been introduced and approved for clinical use in China. So far, some large-scale centers and their experts in China have accumulated rich experience in the application of this technology. However, as a new technology, there are still many blind spots and misunderstandings in its technical promotion and clinical application. Therefore, this paper mainly discusses the basic principles and advantages of irreversible electroporation in the treatment of liver cancer, preoperative case screening, intraoperative operative points, postoperative management, efficacy evaluation, safety and complications, technical disadvantages and limitations, and makes a prospect for the future of irreversible electroporation.

Key words: Irreversible electric ablation technology, Liver cancer, Whole process management strategy

武慧铭, 赵建军. 不可逆电穿孔消融在肝癌治疗中的全流程管理策略[J]. 肝癌电子杂志, 2021, 8(2): 57-61.

Wu Huiming, Zhao Jianjun. The whole process management strategy of irreversible electroporation in the treatment of liver cancer[J]. Electronic Journal of Liver Tumor, 2021, 8(2): 57-61.

参考文献

[1] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].肝癌电子杂志,2020,7(1):5-23.
[2] TORRE L A, BRAY F, SIEGEL R L, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] LAI EC, FAN ST, LO CM, et al.Hepatic resection for hepatocellular carcinoma. An audit of 343 patients[J]. Ann Surg, 1995, 221: 291-298.
[4] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[5] NIESSEN C, THUMANN S, BEYER L, et al.Percutaneous irreversible electroporation: long-term survival analysis of 71 patients with inop-erable malignant hepatic tumors[J]. Sci Rep, 2017, 7: 43687
[6] WAGSTAFF P G, BRUIN D D, ZONDERVAN P J, et al.The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol[J]. Bmc Cancer, 2015, 15(1): 165.
[7] LEE E W, D WONG, PRIKHODKO S V, et al. Electron Microscopic Demonstration and Evaluation of Irreversible Electroporation-Induced Nanopores on Hepatocyte Membranes[J]. J Vasc Interv Radiol. 2012, 23(1): 107-113.
[8] CHANG D C, REESE T S.Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy[J]. Biophys J, 1990, 58(1): 1-12.
[9] RUBINSKY B.Irreversible electroporation in medicine[J]. Technol Cancer Res Treat, 2007, 6(4): 255.
[10] LU D, RAMAN S S, LIMANOND P, et al.Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors[J]. J Vasc Interv Radiol, 2003, 14(10): 1267-1274.
[11] YU N C, RAMAN S S, KIM Y J, et al.Microwave Liver Ablation: Influence of Hepatic Vein Size on Heat-sink Effect in a Porcine Model[J]. J Vasc Interv Radiol, 2008, 19(7): 1087-1092.
[12] BHUTIANI N, PHILIPS P, SCOGGINS CR, et al.Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child- Pugh B (7/8) hepatocellular carcinoma (HCC)[J]. HPB (Oxford), 2016, 18(7), 593-599.
[13] 郭凯,李晓勇,周百中,等.纳米刀消融治疗不可切除肝门部胆管癌的临床价值[J]. 中国普通外科杂志,2020,35(1):78-84.
[14] Narayanan G,Fround T.Pain Analysis in Patients with Hepatocellular Carcinoma: Irreversible Electroporation versus Radiofrequency Ablation—Initial Observations[J]. Cardiovasc Intervent Radiol, 2013, 36(1): 176-182.
[15] VERLOH N, JENSCH I, LüRKEN L, et al. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors[J]. Radiol Oncol. 2019, 53(1): 116-122.
[16] LEE E W, LOH C T, K EE S T. Imaging Guided Percutaneous Irreversible Electroporation: Ultrasound and Immunohistological Correlation[J]. Technol Cancer Res Treat, 2016, 6(4): 287-294.
[17] SUTTER O, CALVO J, G N'KONTCHOU, et al. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series[J]. Radiology, 2017: 877-886.
[18] THOMSON KR, CHEUNG W, ELLIS SJ, et al.Investigation of the safety of irreversible electroporation in humans[J]. Vasc Interv Radiol, 2011, 22: 611-621.
[19] FRÜHLING P,NILSSON A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results[J]. Eur J Surg Oncol, 2017, 43(4): 751-757.
[20] ASHA Z, DAVID G, KEVIN C.Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives[J]. J Hepatocell Carcinoma, 2017, 4: 49-58.
[21] NIESSEN C, JULIANE IGL.et al.Factors Associated with Short-Term Local Recurrence of Liver Cancer after Percutaneous Ablation Using Irreversible Electroporation: A Prospective Single-Center Study[J]. J Vasc Interv Radiol, 2015, 26(5): 694-702.
[22] BALL C, THOMSON K R, KAVNOUDIAS H.Irreversible Electroporation: A New Challenge in "Out of Operating Theater" Anesthesia[J]. Anesth Analg, 2010, 110(5): 1305-1309.
[23] TILBORG A, VIEVEEN J M, KUIJK C V, et al.Anaesthetic management during open and percutaneous irreversible electroporation[J]. Br J Anaesth, 2014, 113(6): 985-992.
[24] MARTIN R C, SCHWARTZ E, ADAMS J A, et al.Intra - operative Anesthesia Management in Patients Undergoing Surgical Irreversible Electroporation of the Pancreas, Liver, Kidney, and Retroperitoneal Tumors[J]. Anesth Pain Med, 2015, 5(2): e22786.
[25] CAI Z, CHEN G, ZENG Y, et al.Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma[J]. Clin Cancer Res, 2019, 25(17): 5284-5294.
[26] CAI Z X, CHEN G, ZENG Y Y, et al.Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985
[27] DOLLINGER M, BEYER L P, HAIMERL M, et al.Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience[J]. Diagn Interv Radiol, 2015, 21(6): 471.
[28] DISTELMAIER M, BARABASCH A, HEIL P, et al.Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins[J]. Radiology, 2017, 285(3): 1023-1031.
[29] WAGSTAFF PG, DE BRUIN DM, VAN DEN BOS W, et al. Irreversible electroporation of the porcine kidney: Temperature development and distribution[J]. Urol Oncol, 2015, 33(4): 168. e1-7.
[30] CHEN X, REN Z, YIN S, et al.The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile[J]. Cytokine, 2017,93: 44-50.
[31] LI X, XU K, LI W, et al.Immunologic Response to Tumor Ablation with Irreversible Electroporation[J]. Plos One, 2012, 7(11): e48749.
[32] BE B ULVIK, ROZENBLUM N, GOUREVICH S, et al.Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model[J]. Radiology, 2016, 280(2): 413.